| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
Crisnatol manufacturers
- Crisnatol
-
- $92.00
-
2026-07-15
- CAS:96389-68-3
- Purity:
- Supply Ability: 10g
|
| | Crisnatol Basic information |
| Product Name: | Crisnatol | | Synonyms: | Crisnatol;2-(Chrysene-6-ylmethylamino)-2-methyl-1,3-propanediol;2-[(Chrysen-6-ylmethyl)amino]-2-methyl-1,3-propanediol;770U-82;BW-A-770U;1,3-Propanediol, 2-((6-chrysenylmethyl)amino)-2-methyl-;Crisnatol [inn];Crisnatolum | | CAS: | 96389-68-3 | | MF: | C23H23NO2 | | MW: | 345.43 | | EINECS: | | | Product Categories: | | | Mol File: | 96389-68-3.mol |  |
| | Crisnatol Chemical Properties |
| form | Solid | | color | White to off-white |
| | Crisnatol Usage And Synthesis |
| Uses | Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts[1][2][3]. | | in vivo | Crisnatol (25 mg/kg; p.o.; single dose) shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography[2]. | | References | [1] Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. Cancer Res. 1989 Dec 1;49(23):6615-20. PMID:1676660
[2] Patel DK, et al. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991 Jul 5;42(2):337-46. DOI:10.1016/0006-2952(91)90721-g
[3] Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. Drug Metab Dispos. 1991 Mar-Apr;19(2):491-7. PMID:1676660 |
| | Crisnatol Preparation Products And Raw materials |
|